FDA Seeks to Monitor Cannabis Conversations on Social Media

The FDA has requested authority to monitor social media conversations about cannabis, CBD, and emerging cannabinoid products to better understand the real-world cannabis market without granting therapeutic authorizations. This federal surveillance initiative represents a significant shift in how U.S. regulatory agencies approach cannabinoid oversight, collecting public data to track consumer discussions and market trends. The move reflects growing recognition that cannabis and CBD use extends far beyond approved medical applications, requiring enhanced regulatory monitoring. For patients and consumers, this development highlights the FDA's evolving approach to market surveillance while maintaining distinction between social media discussions and formal drug approvals. The initiative opens important questions about data collection, privacy implications, and how regulatory agencies balance public health monitoring with patient access to emerging therapeutic options.